guardant health - Search News

Guardant Health, Barclays

Barclays Initiates Coverage of Guardant Health (GH) with Overweight Recommendation

Fintel reports that on January 23, 2025, Barclays initiated coverage of Guardant Health (NasdaqGS:GH) with a Overweight recommendation. Analyst Price Forecast Suggests 12.31% Downside As of December 23,

Business Insider · 2d

Guardant Health initiated with an Overweight at Barclays

Barclays initiated coverage of Guardant Health (GH) with an Overweight rating and $60 price target The firm started the liquid biopsy space

bovnews · 1d

What’s Fueling Guardant Health Inc (GH) Stock’s 76.23% Gain Above Its 200-Day SMA?

In terms of valuation, Guardant Health Inc’s market capitalization stands at $6.00 billion. Market cap represents the total value of all outstanding shares and is a key indicator of a company’s market value. Additionally, the Price-to-Sales Ratio is 8.67, reflecting the market’s valuation of the company’s sales.

Investing.com on MSN · 2d

Barclays initiates Guardant Health stock with Overweight rating

Barclays (LON:BARC) began coverage on Guardant Health (NASDAQ:GH) shares, assigning an Overweight rating and setting a price target of $60. The new outlook comes as Guardant Health, a precision oncology company,

bovnews11h

Guardant Health Inc (GH) Stock Trading Recap

Guardant Health Inc (GH) stock saw a decline, ending the day at $47.21 which represents a decrease of $-1.39 or -2.86% from the prior close of $48.6. The stock opened at $48.26 and touched a low of ...

Guardant Health’s Strategic Growth: Strong Buy Rating Amid Advancements in Reveal MRD Assay

Leerink Partners analyst Puneet Souda has maintained their bullish stance on GH stock, giving a Buy rating yesterday.Invest with Confidence: ...

3don MSN

Why Guardant Health, Inc. (GH) Soared At The Start Of The Trading Week

We recently compiled a list of the 10 Firms Kick Off Trading Week Soaring. In this article, we are going to take a look at ...

Brokers Offer Predictions for Guardant Health Q4 Earnings

Investment analysts at Leerink Partnrs lifted their Q4 2024 earnings per share estimates for Guardant Health in a research report issued on Tuesday, January 21st. Leerink Partnrs analyst P. Souda now ...

Guardant Health Gains Medicare Coverage For Colorectal Cancer Monitoring Test

Guardant Health, Inc. (NASDAQ:GH) announced that Palmetto GBA, a Medicare administrative contractor that administers the ...

Guardant Health: Remains Risky Despite SHIELD's Early Success

Despite Guardant Health's positive Q4 2024 report, it remains unprofitable with negative cash flow, unlike its peer Natera.

FierceBiotech12d

JPM25: Guardant Health posts 31% sales gain as cancer blood tests expand

In an early look at its annual earnings report, Guardant Health posted revenue gains of 31%—with the $737 million total ...

Business Wire2d

Guardant Health to Present Data at ASCO GI Demonstrating the Value of Its Precision Oncology Tools for Cancer Detection, Treatment Decisions and Therapy Development

PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the company and its research collaborators will present data ...

Investor's Business Daily on MSN4d

Why Top 4% Guardant Health Surged To A 13-Month High And Topped A Profit-Taking Zone

Guardant Health stock hit a 13-month high Tuesday after Medicare officials agreed to pay for the company's colon cancer blood test.Please watch the video at Investors.com - The Cell Therapy Market Is ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results

Guardant Health, Barclays

Related topics